{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:58Z","timestamp":1786112818860,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2023\/02691-2"],"award-info":[{"award-number":["2023\/02691-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2025\/23708-6"],"award-info":[{"award-number":["2025\/23708-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104662","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:52:13Z","timestamp":1775231533000},"page":"104662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Protein exosites as drug targets: from structural topology to therapeutic modality"],"prefix":"10.1016","volume":"31","author":[{"given":"Folorunsho Bright","family":"Omage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Mazoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e1cio Henrique","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4982-0416","authenticated-orcid":false,"given":"Goran","family":"Neshich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104662_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104662_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00001721-199102000-00011","article-title":"Thrombin structure and function: why thrombin is the primary target for antithrombotics","volume":"2","author":"Fenton","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.drudis.2026.104662_b0015","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/j.1460-2075.1989.tb08511.x","article-title":"The refined 1.9\u00a0\u00c5 crystal structure of human \u03b1-thrombin","volume":"8","author":"Bode","year":"1989","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2026.104662_b0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1749-6632.1986.tb34563.x","article-title":"Thrombin anion-binding exosite interactions","volume":"485","author":"Fenton","year":"1986","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.drudis.2026.104662_b0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mam.2008.01.001","article-title":"Thrombin","volume":"29","author":"Di Cera","year":"2008","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.drudis.2026.104662_b0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10822-019-00276-y","article-title":"Druggable exosites of the human kino-pocketome","volume":"34","author":"Nicola","year":"2020","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.drudis.2026.104662_b0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/35000065","article-title":"A conserved docking motif in MAP kinases common to substrates, activators and regulators","volume":"2","author":"Tanoue","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0040","article-title":"A curated database of protein exosites for drug discovery","volume":"2025","author":"Omage","year":"2025","journal-title":"Database"},{"key":"10.1016\/j.drudis.2026.104662_b0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cell.2013.03.034","article-title":"Allostery in disease and in drug discovery","volume":"153","author":"Nussinov","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104662_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104662_b0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pharmtox-010611-134514","article-title":"The best of both worlds? Bitopic orthosteric\/allosteric ligands of G protein-coupled receptors","volume":"52","author":"Valant","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2026.104662_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104662_b0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104662_b0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104662_b0075","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104662_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1378\/chest.124.3_suppl.11S","article-title":"Thrombin interactions","volume":"124","author":"Di Cera","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2026.104662_b0085","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1538-7836.2005.01363.x","article-title":"Molecular recognition mechanisms of thrombin","volume":"3","author":"Huntington","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2026.104662_b0090","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104662_b0095","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104662_b0100","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104662_b0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1126\/science.2374926","article-title":"The structure of a complex of recombinant hirudin and human alpha-thrombin","volume":"249","author":"Rydel","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104662_b0110","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1021\/bi00364a025","article-title":"Kinetics of the inhibition of thrombin by hirudin","volume":"25","author":"Stone","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104662_b0115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41589-019-0271-0","article-title":"Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme","volume":"15","author":"Maianti","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0083-6729(08)00622-5","article-title":"Structure, function, and regulation of insulin-degrading enzyme","volume":"80","author":"Hulse","year":"2009","journal-title":"Vitam Horm"},{"key":"10.1016\/j.drudis.2026.104662_b0125","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2005-04-1710","article-title":"Directing thrombin","volume":"106","author":"Lane","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104662_b0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/355564a0","article-title":"Selection of single-stranded DNA molecules that bind and inhibit human thrombin","volume":"355","author":"Bock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104662_b0135","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations","volume":"295","author":"Coussens","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104662_b0140","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1189\/jlb.1006629","article-title":"Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins","volume":"81","author":"Piccard","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0145","doi-asserted-by":"crossref","first-page":"35944","DOI":"10.1074\/jbc.M109.091769","article-title":"Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides","volume":"285","author":"Dufour","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104662_b0150","doi-asserted-by":"crossref","first-page":"33167","DOI":"10.1074\/jbc.M111.256644","article-title":"Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration","volume":"286","author":"Zarrabi","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104662_b0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcdb.2007.06.006","article-title":"MMPs as therapeutic targets \u2013 still a viable option?","volume":"19","author":"Fingleton","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0160","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","article-title":"Differential regulation and properties of MAPKs","volume":"26","author":"Raman","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104662_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003004","article-title":"Specificity of linear motifs that bind to a common mitogen-activated protein kinase docking groove","volume":"5","author":"Garai","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2026.104662_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1097-2765(04)00161-3","article-title":"Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry","volume":"14","author":"Lee","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104662_b0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.toxicon.2008.12.027","article-title":"Receptor and substrate interactions of clostridial neurotoxins","volume":"54","author":"Brunger","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.drudis.2026.104662_b0180","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.ade2574","article-title":"Evolutionary-scale prediction of atomic-level protein structure with a language model","volume":"379","author":"Lin","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104662_b0185","article-title":"Protein family membership governs exosite predictability across the structural proteome","author":"Omage","year":"2026","journal-title":"Artif Intell Life Sci"},{"key":"10.1016\/j.drudis.2026.104662_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sbi.2017.10.002","article-title":"Structure-based prediction of protein allostery","volume":"50","author":"Greener","year":"2018","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sbi.2015.10.004","article-title":"Allosteric sites: remote control in regulation of protein activity","volume":"37","author":"Guarnera","year":"2016","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103551","article-title":"AlphaFold, allosteric, and orthosteric drug discovery: ways forward","volume":"28","author":"Nussinov","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104662_b0205","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1021\/jm100574m","article-title":"Understanding and predicting druggability. A high-throughput method for detection of drug binding sites","volume":"53","author":"Schmidtke","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104662_b0210","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1021\/acs.jmedchem.6b01601","article-title":"Bitopic ligands and metastable binding sites: opportunities for G protein-coupled receptor medicinal chemistry","volume":"60","author":"Fronik","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104662_b0215","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nchembio.2431","article-title":"A kinetic view of GPCR allostery and biased agonism","volume":"13","author":"Lane","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0220","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104662_b0225","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104662_b0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev-biochem-060713-035456","article-title":"Selection-based discovery of druglike macrocyclic peptides","volume":"83","author":"Passioura","year":"2014","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2026.104662_b0235","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1021\/acs.chemrev.8b00430","article-title":"RNA display methods for the discovery of bioactive macrocycles","volume":"119","author":"Huang","year":"2019","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2026.104662_b0240","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.sbi.2013.08.001","article-title":"Allosteric inhibition of BACE1 by an exosite-binding antibody","volume":"23","author":"Wang","year":"2013","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2026.104662_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00610","article-title":"Discovery of an APP-selective BACE1 inhibitor for Alzheimer\u2019s disease","volume":"22","author":"Campagna","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2026.104662_b0250","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41598-020-80294-1","article-title":"Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide","volume":"11","author":"Santamaria","year":"2021","journal-title":"Sci Rep"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462600067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:22:23Z","timestamp":1785946943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462600067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S135964462600067X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104662","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein exosites as drug targets: from structural topology to therapeutic modality","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104662"}}